tetano
Editor, Senior Moderator
Hemasphere
. 2021 Dec 17;6(1):e677.
doi: 10.1097/HS9.0000000000000677. eCollection 2022 Jan.
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
Evangelos Terpos[SUP] 1 [/SUP], Vangelis Karalis[SUP] 2 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 1 [/SUP], Filia Apostolakou[SUP] 3 [/SUP], Sentiljana Gumeni[SUP] 4 [/SUP], Maria Gavriatopoulou[SUP] 1 [/SUP], Dimitris Papadopoulos[SUP] 2 [/SUP], Panagiotis Malandrakis[SUP] 1 [/SUP], Eleni-Dimitra Papanagnou[SUP] 4 [/SUP], Eleni Korompoki[SUP] 1 [/SUP], Efstathios Kastritis[SUP] 1 [/SUP], Ioannis Papassotiriou[SUP] 3 [/SUP], Ioannis P Trougakos[SUP] 4 [/SUP], Meletios A Dimopoulos[SUP] 1 [/SUP]
Affiliations
Abstract
The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript's cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks.
. 2021 Dec 17;6(1):e677.
doi: 10.1097/HS9.0000000000000677. eCollection 2022 Jan.
Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
Evangelos Terpos[SUP] 1 [/SUP], Vangelis Karalis[SUP] 2 [/SUP], Ioannis Ntanasis-Stathopoulos[SUP] 1 [/SUP], Filia Apostolakou[SUP] 3 [/SUP], Sentiljana Gumeni[SUP] 4 [/SUP], Maria Gavriatopoulou[SUP] 1 [/SUP], Dimitris Papadopoulos[SUP] 2 [/SUP], Panagiotis Malandrakis[SUP] 1 [/SUP], Eleni-Dimitra Papanagnou[SUP] 4 [/SUP], Eleni Korompoki[SUP] 1 [/SUP], Efstathios Kastritis[SUP] 1 [/SUP], Ioannis Papassotiriou[SUP] 3 [/SUP], Ioannis P Trougakos[SUP] 4 [/SUP], Meletios A Dimopoulos[SUP] 1 [/SUP]
Affiliations
- PMID: 34938959
- PMCID: PMC8687721
- DOI: 10.1097/HS9.0000000000000677
Abstract
The sustainability of coronavirus 19 (COVID-19) vaccine-induced immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to be determined to inform public health decisions on vaccination programs and prevention measures against COVID-19. The aim of the present study was to prospectively evaluate the kinetics of neutralizing antibodies (NAbs) and anti-S-receptor binding domain (RBD IgGs) against SARS-CoV-2 after full vaccination with the BNT162b2 mRNA vaccine for up to 9 months in healthy individuals (NCT04743388). The assessments were performed at the following time points after the second vaccination: 2 weeks, 1 month, 3 months, 6 months, and 9 months. The measurements were performed with the GenScript's cPassTM SARS-CoV-2 NAbs Detection Kit (GenScript, Inc.; Piscataway, NJ) and the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH; Mannheim, Germany). Three hundred nine participants with a median age of 48 years were included. A gradual decline in both NAbs and anti-S-RBD IgGs became evident from 2 weeks to 9 months postvaccination. Both NAbs and anti-S-RBD IgGs levels were significantly lower at 9 months compared with the previous timepoints. Interestingly, age was found to exert a statistically significant effect on NAbs elimination only during the first-trimester postvaccination, as older age was associated with a more rapid clearance of NAbs. Furthermore, simulation studies predicted that the median NAb value would fall from 66% at 9 months to 59% and 45% at 12 and 18 months postvaccination, respectively. This finding may reflect a declining degree of immune protection against COVID-19 and advocates for the administration of booster vaccine shots especially in areas with emerging outbreaks.